文献速递肝胆胰外科

晚期胰腺癌新辅助治疗后病理完全缓解患者的复发特征与治疗

Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer.
PubMed 文献 · Ann Surg · 2021-01-01

该研究回顾2009至2017年间331例接受新辅助治疗的临界可切除或局部晚期胰腺导管腺癌患者,其中30例达到病理完全缓解(pCR)。pCR患者中位无病生存期29个月、总生存期76个月,14例出现复发,复发后中位生存25个月;部分复发患者经化疗、放疗、消融或手术切除后仍长期存活。

要点

  • 晚期PDAC新辅助治疗后达pCR者预后显著改善,中位OS达76个月。
  • pCR患者仍有约半数出现复发,中位DFS为29个月。
  • 复发后治疗包括化疗、放疗、消融和手术切除,中位PRS为25个月。

核心结论

  • 晚期PDAC新辅助治疗后达到pCR与显著生存改善相关,但约半数患者仍会出现复发。
  • pCR患者复发后对治疗反应良好,生存结局仍令人鼓舞。

研究设计与样本

  • 回顾性队列研究,纳入2009至2017年间接受新辅助治疗并因晚期PDAC行胰腺切除术的患者。
  • 331例临界可切除或局部晚期PDAC患者中,30例达到pCR。
  • 采用Cox回归模型分析复发相关因素。

主要发现

  • pCR患者中位DFS为29个月,中位OS为76个月。
  • 14例pCR患者出现复发。
  • 未发现与生存相关的临床病理或治疗特征。
  • 复发后中位PRS为25个月。
  • 2例患者分别接受肝切除或完成性胰腺切除后,至随访时仍存活13个月和62个月。

临床怎么用

  • pCR患者仍需密切随访监测复发。
  • 复发后可综合采用化疗、放疗、消融或手术切除等治疗方式。
  • 对pCR后复发患者,积极治疗仍可能获得较长生存。

局限性

  • 研究为回顾性设计,pCR患者样本量较小(30例)。
  • 原文未报告复发相关因素的具体分析结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to characterize the patterns and treatment of disease recurrence in patients achieving a pathological complete response (pCR) following neoadjuvant chemoradiation for advanced pancreatic ductal adenocarcinoma (PDAC). SUMMARY OF BACKGROUND DATA: A pCR is an independent predictor for improved survival in PDAC. However, disease recurrence is still observed in these patients. METHODS: Patients with advanced PDAC who were treated with neoadjuvant therapy and had a pCR were identified between 2009 and 2017. Overall survival (OS) was determined from the initiation of neoadjuvant, disease-free survival (DFS) from the date of surgery, and post-recurrence survival (PRS) from the date of recurrence. Factors associated with recurrence were analyzed using a Cox-regression model. RESULTS: Of 331 patients with borderline resectable or locally advanced PDAC, 30 achieved a pCR following neoadjuvant treatment and pancreatectomy. The median DFS for pCR patients was 29 months and OS 76 months. Recurrence was observed in 14 patients. No clinicopathologic or treatment characteristics were associated with survival. The median PRS following recurrence was 25 months. Treatment following recurrence included chemotherapy, radiation or ablation, and surgical resection. Hepatectomy or completion pancreatectomy was accomplished in 2 patients that remain alive 13 and 62 months, respectively, following metastasectomy. CONCLUSIONS: A pCR following neoadjuvant therapy in patients with advanced PDAC is associated with remarkable survival, although recurrence occurs in about half of patients. Nevertheless, patients with pCR and recurrence respond well to treatment and survival remains encouraging. Advanced molecular characterization and longitudinal liquid biopsy may offer additional assistance with understanding tumor biologic behavior after achieving a pCR.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Blair AB, Yin LD, Pu N, et al. Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer. Ann Surg. 2021. PMID: 32304375. doi:10.1097/SLA.0000000000003570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。